Severe Cutaneous Adverse Reactions to Drugs

Faith L. Chia; Khai Pang Leong


Curr Opin Allergy Clin Immunol. 2007;7(4):304-309. 

In This Article


SJS and TEN are rare but serious conditions with significant mortality rates, reflecting the inadequacy of current available treatment. Early withdrawal of causative drugs and meticulous supportive therapy still form the cornerstone of treatment. The use of IVIg is supported by most studies, albeit uncontrolled ones. The use of anti-TNF monoclonal antibodies appears promising with dramatic success in two cases so far. Recent understanding of pathogenic mechanisms may lead to therapies that target other mediators of apoptosis. Multicentre studies and collaborations such as the RegiSCAR project are needed to establish effective treatment protocols for these uncommon conditions.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: